Mohanad Mossalam, Ph.D.

Technology Specialist, Registered Patent Agent - Boston

Mohanad Mossalam
Download Media Photo

Contact Information

Mohanad Mossalam is a technology specialist in Foley Hoag’s Intellectual Property Department. He assists in preparation and prosecution of U.S. and foreign patent applications in the areas of biotechnology, chemistry, and pharmaceuticals. He also assists teams in client advocacy and due diligence by investigating scientific technology underlying inventions.

Dr. Mossalam has a strong background in molecular cell biology, and extensive research experience in genome editing and small molecule drug discovery.

More »


  • University of Utah, Ph.D., Pharmaceutics and Pharmaceutical Chemistry, 2012
  • University of Utah, B.S., Chemistry, 2005


English, Arabic

Professional Experience

  • Postdoctoral Fellow, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
  • Over 15 years of scientific research experience in molecular biology, genome editing and small molecule drug discovery.
  • Co-Author, “Presenilins regulate synaptic plasticity and mitochondrial calcium homeostasis in the hippocampal mossy fiber pathway, Mol. Neurodegener. 2017 12(1):48
  • Co-First Author, “A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells,” Mol. Pharm. 2013 10(10):3922-33
  • Co-First Author, “Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2,” Mol. Phar. 2013 10(4):1340-9
  • First Author, “Solid phase synthesis of mitochondrial triphenylphosphonium-vitamin E metabolite using a lysine linker for reversal of oxidative stress,” PLoS One. 2013 8(1):e53272
  • Co-Author, “Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered Bcr-Abl binding protein and Imatinib,” Mol. Pharm. 2012 9(11):3318-29
  • Co-Author, “Utilizing the estrogen receptor ligand-binding domain for controlled protein translocation to the insoluble fraction,” Pharm. Res. 2012 29(12):3455-63
  • First Author, “Direct induction of apoptosis using an optimal mitochondrially targeted p53,” Mol. Pharm. 2012 9(5):1449-58
  • First Author, “Controlling subcellular delivery to optimize therapeutic effect,” Ther. Deliv. 2010 1(1):169-193


  • Peer Mentor Award, Brigham and Women’s Hospital, Harvard Medical School
  • Ruth L. Kirschstein National Research Service Award (NIH-T32), Harvard Medical School
  • Wolf Prize in Teaching Excellence, College of Pharmacy, University of Utah


  • Boston Patent Law Association, Member